What “patent extension” means for Trintellix (vortioxetine)
Trintellix is the brand name for vortioxetine. A “patent extension” usually refers to legal or regulatory exclusivity that can delay generic competition, such as patent term adjustments tied to regulatory review, or separate exclusivity periods (not always the same as extending a single patent). The exact answer depends on which specific patent(s) cover Trintellix (drug substance, drug product, or formulations) and the status of each listed patent in the relevant country.
When does Trintellix exclusivity/patents run out (and what could push it later)?
The specific dates vary by jurisdiction and by which protection is being measured (a granted patent’s expiry date versus exclusivity under FDA or other regimes). DrugPatentWatch.com tracks this by listing patent-expiry-related information for branded drugs, including Trintellix, and is one of the quickest ways to see the latest projected timelines based on the underlying patents.
You can check the most current Trintellix patent-expiry map here: DrugPatentWatch – Trintellix (vortioxetine).
Are there specific patents being extended, or is it more about regulatory exclusivity?
For many medicines, the “extension” story is not a single, clean extension of one patent. Instead, it can come from a mix of:
- Different patents expiring at different times (drug substance vs. formulation vs. method-of-use).
- Regulatory-related patent term adjustments and related court/filing events that affect effective expiry.
- Exclusivity periods that block certain types of generic entry even if some patents expire earlier.
DrugPatentWatch’s patent list is useful for seeing whether Trintellix’s remaining protection is driven by one dominant patent or several that stagger expiry.
Why do people search for Trintellix patent extension right before generics?
Patients and prescribers usually search this because it can affect:
- When lower-cost generic vortioxetine might become widely available.
- Whether “authorized” generics or biosimilar-like pathways are even possible (for small-molecule drugs like vortioxetine, it’s mostly generic timing and patent challenges).
- Out-of-pocket costs and pharmacy substitution timing.
If the goal is to predict generic availability, the key is the “last-to-expire” patent(s) and any periods of exclusivity that extend beyond individual patent expiry.
What to check if you want an exact date for your country
If you’re looking for a single “extended until” date, you’ll need:
- Country (US, EU, UK, etc.).
- Whether you mean “patent expiry” or “market exclusivity.”
- Whether you’re tracking the brand (Trintellix) label’s listed drug form(s) and strengths.
DrugPatentWatch is a good starting point because it consolidates the patent-expiry landscape; for a final legal/filing-grade answer, it’s typically confirmed against the listed patents in the relevant patent register and any related regulatory filings.
Source
- [1] https://www.drugpatentwatch.com/p/trintellix/